Figure 2.

Figure 2.

Proportion of Patients with FVC Change from Baseline of Bexotegrast 320 mg Over 12 and 24 Weeks versus Placebo - Intent to Treat Population

Format

JPEG

Source

Pliant Therapeutics, Inc.

Downloads